Attovia Therapeutics, Inc. (NASDAQ:ATTO) Sees Large Increase in Short Interest

Attovia Therapeutics, Inc. (NASDAQ:ATTO) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 511,865 shares, an increase of ? from the July 30th total of 0 shares. Based on an average daily trading volume, of 732,925 shares, the short-interest ratio is currently 0.7 days. Approximately 1.2% of the shares of the company are sold short.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Leerink Partners assumed coverage on shares of Attovia Therapeutics in a research report on Monday. They issued an “outperform” rating and a $52.00 price objective for the company. Morgan Stanley assumed coverage on Attovia Therapeutics in a research note on Monday. They set an “overweight” rating and a $39.00 target price for the company. Citigroup began coverage on Attovia Therapeutics in a report on Monday. They issued a “buy” rating and a $30.00 price target for the company. Finally, Royal Bank Of Canada began coverage on Attovia Therapeutics in a research note on Monday. They issued an “outperform” rating and a $45.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $41.50.

Attovia Therapeutics Stock Down 0.1%

Shares of ATTO opened at $20.67 on Monday. Attovia Therapeutics has a 52-week low of $16.15 and a 52-week high of $24.32.

Insider Buying and Selling

In other news, major shareholder Redmile Group, Llc acquired 400,000 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was bought at an average price of $17.00 per share, for a total transaction of $6,800,000.00. Following the transaction, the insider owned 1,182,854 shares in the company, valued at $20,108,518. This represents a 51.10% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Goldman Sachs Group Inc acquired 500,000 shares of the business’s stock in a transaction on Thursday, August 6th. The shares were purchased at an average price of $17.00 per share, with a total value of $8,500,000.00. Following the transaction, the insider owned 3,020,632 shares in the company, valued at $51,350,744. The trade was a 19.84% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 2,740,587 shares of company stock worth $47,269,979 in the last ninety days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. grew its stake in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO) by 23.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the period. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent reporting period.

Attovia Therapeutics Company Profile

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.